BLASUBCUTANEOUSINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) by Roche is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2020.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHESGO is a subcutaneous fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf that targets HER2/neu receptors in HER2-positive breast cancer. This monoclonal antibody combination works by blocking HER2-driven tumor growth through dual pathway inhibition. The hyaluronidase component enables subcutaneous delivery, improving patient convenience compared to intravenous administration.
$0.001BPart D
PeakPHESGO is in peak revenue phase but represents a smaller Part D segment ($1M in 2023 with 139 claims), suggesting focused adoption in specific patient populations with growth potential as physician familiarity increases.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Started Jul 2024
165 enrolled
HER2-positive Breast Cancer
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Started Sep 2023
230 enrolled
Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Started Jul 2022
922 enrolled
Locally Advanced or Metastatic Breast Cancer
Worked on PHESGO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.